MX2023012131A - Construcciones de il-2. - Google Patents

Construcciones de il-2.

Info

Publication number
MX2023012131A
MX2023012131A MX2023012131A MX2023012131A MX2023012131A MX 2023012131 A MX2023012131 A MX 2023012131A MX 2023012131 A MX2023012131 A MX 2023012131A MX 2023012131 A MX2023012131 A MX 2023012131A MX 2023012131 A MX2023012131 A MX 2023012131A
Authority
MX
Mexico
Prior art keywords
based constructs
protein complexes
chimeric protein
chimeric
interleukin
Prior art date
Application number
MX2023012131A
Other languages
English (en)
Spanish (es)
Inventor
Erik Depla
Lennart Zabeau
Nikolai Kley
Anje Cauwels
Original Assignee
Orionis Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orionis Biosciences Inc filed Critical Orionis Biosciences Inc
Publication of MX2023012131A publication Critical patent/MX2023012131A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023012131A 2021-04-16 2022-04-16 Construcciones de il-2. MX2023012131A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163175827P 2021-04-16 2021-04-16
US202263297330P 2022-01-07 2022-01-07
PCT/US2022/025143 WO2022221746A1 (en) 2021-04-16 2022-04-16 Il-2 based constructs

Publications (1)

Publication Number Publication Date
MX2023012131A true MX2023012131A (es) 2024-01-11

Family

ID=83639788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012131A MX2023012131A (es) 2021-04-16 2022-04-16 Construcciones de il-2.

Country Status (9)

Country Link
US (1) US20240199714A1 (enExample)
EP (1) EP4323392A4 (enExample)
JP (1) JP2024522949A (enExample)
KR (1) KR20240021155A (enExample)
AU (1) AU2022258840A1 (enExample)
CA (1) CA3215204A1 (enExample)
IL (1) IL307574A (enExample)
MX (1) MX2023012131A (enExample)
WO (1) WO2022221746A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CA3165927A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4626486A2 (en) * 2022-11-30 2025-10-08 The Regents of University of California Multispecific engineered biomolecules and uses thereof
WO2024119193A2 (en) * 2022-12-02 2024-06-06 AskGene Pharma, Inc. Mutant il-2 polypeptides and il-2 prodrugs
WO2026015864A1 (en) * 2024-07-12 2026-01-15 Outpace Bio, Inc. Cd8 binding polypeptides and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
AU2015301936B2 (en) * 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
CR20170510A (es) * 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
JP7422480B2 (ja) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
EP3538548A4 (en) * 2016-11-08 2020-08-19 Delinia, Inc. IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
JP7148539B2 (ja) * 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
US10676516B2 (en) * 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
KR102777151B1 (ko) * 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
PE20210313A1 (es) * 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
KR20210005872A (ko) * 2018-03-28 2021-01-15 오리오니스 바이오사이언시즈 인코포레이티드 이작용성 단백질 및 이의 작제물
KR20250156190A (ko) * 2018-06-22 2025-10-31 큐진 인크. 인터루킨-2 변이체 및 이의 사용 방법
EP3980051A4 (en) * 2019-06-05 2023-09-13 Asher Biotherapeutics, Inc. FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS
WO2020252421A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants and bifunctional fusion molecules thereof

Also Published As

Publication number Publication date
US20240199714A1 (en) 2024-06-20
KR20240021155A (ko) 2024-02-16
IL307574A (en) 2023-12-01
EP4323392A4 (en) 2025-03-19
CA3215204A1 (en) 2022-10-20
EP4323392A1 (en) 2024-02-21
JP2024522949A (ja) 2024-06-24
AU2022258840A1 (en) 2023-10-26
WO2022221746A1 (en) 2022-10-20
AU2022258840A9 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
MX2023012131A (es) Construcciones de il-2.
MY206158A (en) Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
MY190686A (en) Anti-vegf protein compositions and methods for producing the same
NZ800435A (en) Interleukin-18 variants and methods of use
PH12020500648A1 (en) Il-15 variants and uses thereof
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
WO2005021592A3 (en) Enhancing the circulating half-life of interleukin-2 proteins
WO2020142625A3 (en) Compositions for increasing half-life of a therapeutic agent in canines and methods of use
WO2020086758A8 (en) Heterodimeric fc-fused proteins
MX2019009255A (es) Proteínas quiméricas dirigidas y sus usos.
MY191030A (en) Gdf15 fusion proteins and uses thereof
MX2022009302A (es) Compuestos de unión a il-7r¿.
MX2021008207A (es) Proteínas de fusión multifuncionales y usos de las mismas.
CY1108387T1 (el) Ανταγωνιστες ανασυνδυασμενης il-18 χρησιμοι στη θεραπεια παθησεων που εμφανιζονται με διαμεσολαβηση της il-18
SI1641483T1 (sl) Fuzijski proteini
ATE541580T1 (de) Selbst anordnende peptid-amphiphile und relevante verfahren für die abgabe von wachstumsfaktor
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
WO2022235622A3 (en) Cd20 targeting fusion proteins and methods of use thereof
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
SA522432487B1 (ar) مشتقات علاجية من إنترلوكين-22
EP4374913A3 (en) Novel human serum albumin mutant
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
MX2025010859A (es) Polipéptidos de fusión dap10/dap12.
SG11202000115SA (en) Novel therapeutic enzyme fusion protein and use thereof
WO2018116165A3 (en) Therapeutically active complexes